Skip to main content
SpringerLink
Log in

Fingolimod: an oral disease-modifying therapy for relapsing multiple sclerosis

  • Review
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

This paper presents a summary of the current knowledge of the mechanism of action of fingolimod (FTY720; Gilenya®; Novartis Pharma Stein AG, Stein, Switzerland) and the phase 2 and 3 studies that have been performed on the drug. This study will discuss specific safety issues that should be considered when initiating this therapy. Multiple sclerosis (MS), an inflammatory disease of the central nervous system, is considered to be a leading cause of neurologic disability in young adults, and predominantly affects young women. The past two decades have seen significant growth in therapeutic options for relapsing forms of MS, including FTY720. Fingolimod (FTY720) is a sphingosine-1-phosphate receptor modulator, and currently the approved dosage is 0.5 mg daily. Notable side effects include bradycardia in the first hours after administration and macular edema. There may be an increased risk of herpetic infections (varicella zoster virus and herpes simplex virus) associated with this medication. This oral therapy has been shown to be effective in double-blind, placebocontrolled studies, and in trials comparing it to weekly interferon beta-1a therapy. However, the long-term efficacy and safety of this oral medication in relapsing MS, including the effect on reduction of disability progression and cognitive decline, remains to be established.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Koch-Henriksen N, Sorensen PS. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol. 2010;9:520–532.

    Article  PubMed  Google Scholar 

  2. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996;46:907–911.

    PubMed  CAS  Google Scholar 

  3. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. New Engl J Med. 2008;358:676–688.

    Article  PubMed  CAS  Google Scholar 

  4. Bar-Or A, Calabresi PA, Arnold D, et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol. 2008;63:395–400.

    Article  PubMed  CAS  Google Scholar 

  5. Bielekova B, Richert N, Howard T, et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci U S A. 2004;101:8705–8708.

    Article  PubMed  CAS  Google Scholar 

  6. Krishnan C, Kaplin AI, Brodsky RA, et al. Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis. Arch Neurol. 2008;65:1044–1051.

    Article  PubMed  Google Scholar 

  7. Then Bergh F, Kumpfel T, Schumann E, et al. Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis-reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations. BMC Neurol. 2006;6:19.

    Article  PubMed  Google Scholar 

  8. Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. Lancet. 1997;349:589–593.

    Article  PubMed  CAS  Google Scholar 

  9. Giovannoni G, Comi G, Cook S, et al. A placebocontrolled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362:416–426.

    Article  PubMed  CAS  Google Scholar 

  10. Kappos L, Radue EW, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362:387–401.

    Article  PubMed  CAS  Google Scholar 

  11. Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol. 2010;33:91–101.

    Article  PubMed  CAS  Google Scholar 

  12. Adachi K, Chiba K. FTY720 story. Its discovery and the following accelerated development of sphingosine 1-phosphate receptor agonists as immunomodulators based on reverse pharmacology. Perspect Medicin Chem. 2008;1:11–23.

    Google Scholar 

  13. Kluepfel D, Bagli J, Baker H, Charest MP, Kudelski A. Myriocin, a new antifungal antibiotic from Myriococcum albomyces. J Antibiot. 1972;25:109–115.

    PubMed  CAS  Google Scholar 

  14. Fujita T, Inoue K, Yamamoto S, et al. Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite. J Antibiot. 1994;47:208–215.

    PubMed  CAS  Google Scholar 

  15. Okajima F. Plasma lipoproteins behave as carriers of extracellular sphingosine 1-phosphate: is this an atherogenic mediator or an anti-atherogenic mediator? Biochim Biophys Acta. 2002;1582:132–137.

    PubMed  CAS  Google Scholar 

  16. Allende ML, Yamashita T, Proia RL. G-proteincoupled receptor S1P1 acts within endothelial cells to regulate vascular maturation. Blood. 2003;102:3665–3667.

    Article  PubMed  CAS  Google Scholar 

  17. Mizugishi K, Yamashita T, Olivera A, Miller GF, Spiegel S, Proia RL. Essential role for sphingosine kinases in neural and vascular development. Mol Cell Biol. 2005;25:11113–11121.

    Article  PubMed  CAS  Google Scholar 

  18. Takabe K, Paugh SW, Milstien S, Spiegel S. “Insideout” signaling of sphingosine-1-phosphate: therapeutic targets. Pharmacol Rev. 2008;60:181–195.

    Article  PubMed  CAS  Google Scholar 

  19. Brinkmann V. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther. 2007;115:84–105.

    Article  PubMed  CAS  Google Scholar 

  20. Siehler S, Manning DR. Pathways of transduction engaged by sphingosine 1-phosphate through G protein-coupled receptors. Biochim Biophys Acta. 2002;1582:94–99.

    PubMed  CAS  Google Scholar 

  21. Brinkmann V, Davis MD, Heise CE, et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem. 2002;277:21453–21457.

    Article  PubMed  CAS  Google Scholar 

  22. Fujino M, Funeshima N, Kitazawa Y, et al. Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J Pharmacol Exp Ther. 2003;305:70–77.

    Article  PubMed  CAS  Google Scholar 

  23. Webb M, Tham CS, Lin FF, et al. Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice. J Neuroimmunol. 2004;153:108–121.

    Article  PubMed  CAS  Google Scholar 

  24. Mehling M, Lindberg R, Raulf F, et al. Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis. Neurology. 2010;75:403–410.

    Article  PubMed  CAS  Google Scholar 

  25. Sawicka E, Dubois G, Jarai G, et al. The sphingosine 1-phosphate receptor agonist FTY720 differentially affects the sequestration of CD4+/CD25+ T-regulatory cells and enhances their functional activity. J Immunol. 2005;175:7973–7980.

    PubMed  CAS  Google Scholar 

  26. Kim HJ, Jung CG, Dukala D, et al. Fingolimod and related compounds in a spontaneous autoimmune polyneuropathy. J Neuroimmunol. 2009;214:93–100.

    Article  PubMed  CAS  Google Scholar 

  27. Zhou PJ, Wang H, Shi GH, Wang XH, Shen ZJ, Xu D. Immunomodulatory drug FTY720 induces regulatory CD4(+)CD25(+) T cells in vitro. Clin Exp Immunol. 2009;157:40–47.

    Article  PubMed  CAS  Google Scholar 

  28. Wolf AM, Eller K, Zeiser R, et al. The sphingosine 1-phosphate receptor agonist FTY720 potently inhibits regulatory T cell proliferation in vitro and in vivo. J Immunol. 2009;183:3751–3760.

    Article  PubMed  CAS  Google Scholar 

  29. Brinkmann V. FTY720 (fingolimod) in multiple sclerosis: therapeutic effects in the immune and the central nervous system. Br J Pharmacol. 2009;158:1173–1182.

    Article  PubMed  CAS  Google Scholar 

  30. Matloubian M, Lo CG, Cinamon G, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature. 2004;427:355–360.

    Article  PubMed  CAS  Google Scholar 

  31. Van Doorn R, Van Horssen J, Verzijl D, et al. Sphingosine 1-phosphate receptor 1 and 3 are upregulated in multiple sclerosis lesions. Glia. 2010;58:1465–1476.

    PubMed  Google Scholar 

  32. Suzuki S, Enosawa S, Kakefuda T, et al. A novel immunosuppressant, FTY720, with a unique mechanism of action, induces long-term graft acceptance in rat and dog allotransplantation. Transplantation. 1996;61:200–205.

    Article  PubMed  CAS  Google Scholar 

  33. Chiba K, Hoshino Y, Suzuki C, et al. FTY720, a novel immunosuppressant possessing unique mechanisms. I. Prolongation of skin allograft survival and synergistic effect in combination with cyclosporine in rats. Transplant Proc. 1996;28:1056–1059.

    PubMed  CAS  Google Scholar 

  34. Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med. 2006;355:1124–1140.

    Article  PubMed  CAS  Google Scholar 

  35. O’Connor P, Comi G, Montalban X, et al. Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology. 2009;72:73–79.

    Article  PubMed  Google Scholar 

  36. Comi G, O’Connor P, Montalban X, et al. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Mult Scler. 2010;16:197–207.

    Article  PubMed  CAS  Google Scholar 

  37. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362:402–415.

    Article  PubMed  CAS  Google Scholar 

  38. Wei Y, Yemisci M, Kim HH, et al. Fingolimod provides long-term protection in rodent models of cerebral ischemia. Ann Neurol. 2011;69:119–129.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Women and Children’s Hospital of Buffalo, 219 Bryant Street, Buffalo, NY, 14222, USA

    E. Ann Yeh

  2. E2, Buffalo General Hospital, Jacobs Neurological Institute, 100 High Street, Buffalo, NY, 14203, USA

    B. Weinstock-Guttman

Authors
  1. E. Ann Yeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. Weinstock-Guttman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B. Weinstock-Guttman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yeh, E.A., Weinstock-Guttman, B. Fingolimod: an oral disease-modifying therapy for relapsing multiple sclerosis. Adv Therapy 28, 270–278 (2011). https://doi.org/10.1007/s12325-011-0004-6

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-011-0004-6

Keywords

Search

Navigation